Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692647 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT06692647 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 19 participants.
The verdict
NCT06692647, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to MK-4318 in a person's body over time. Researchers will compare what happens to levels of MK-4318 in people's blood when it is taken with and without diltiazem. Researchers also want to learn about the safety of MK-4318 taken with and without diltiazem and if people tolerate them.
Interventions
- DRUG Diltiazem
- DRUG MK-4318
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06692647
The ClinicalTrials.gov registry entry for NCT06692647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diltiazem is the first listed.
NCT06692647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06692647 about?
NCT06692647 is a clinical study titled "A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)". The goal of this study is to learn what happens to MK-4318 in a person's body over time. Researchers will compare what happens to levels of MK-4318 in people's blood when it is taken with and without diltiazem. Researchers also want to learn about the safety of MK-4318 taken with and without diltiaz...
What is the current status of trial NCT06692647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-02-09. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT06692647?
The interventions under investigation include: Diltiazem (DRUG), MK-4318 (DRUG).
Who is sponsoring clinical trial NCT06692647?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.